Rhinomed Share Price and Company Fundamentals



Price
$0.36
Change
-0.005 (-1.370%)
52 week
0.1 - 0.485

Last traded: Last Friday at 5:51 AM

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; and Pronto for nasal congestion and sleep disturbance issues. It also engages in developing applications for the delivery of medical cannabis and conditions, including anxiety, pain, allergies, nausea, anxiety, and coughs and colds; and nasal swab to test the presence of upper respiratory tract diseases, including influenza, and coronavirus strains. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Richmond, Australia.

Key Metrics

PE ratio

-

PB ratio

18.95

Dividend yield

Beta

0.64

Market cap

$91.37M

Enterprise value

$89.5M

Company profile

Primary activitiesThe licensing, distribution and/or manufacturing of pharmaceutical and healthcare products.
Industry / SectorMedical Devices / Healthcare
Websitehttp://www.rhinomed.global
Mailing address132 Gwynne Street Level 1 Cremorne Richmond VIC 3121 Australia
Phone / Fax61 3 8416 0900 / 61 3 8080 0796
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Rhinomed does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Rhinomed.

NameTitleAgeTotal Pay
Mr. Michael JohnsonCEO, MD & Exec. Director445k
Mr. Sean SlatteryCFO & Company Sec.308.33k

Profitability and management effectiveness

Profit margin

-185.98%

Operating margin

-185.71%

Return on assets

-55.70%

Return on equity

-110.60%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Rhinomed is 91.37M and its enterprise value is 89.5M. The enterprise value to revenue ratio of RNO is 19.27.

The RNO's stocks Beta value is 0.64 making it 36% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Rhinomed (RNO)

Rhinomed (ASX:RNO) Frequently Asked Questions

1. What is Rhinomed's Stock Symbol?

Rhinomed trades on ASX under the ticker symbol "RNO".

2. What is Rhinomed's stock price today?

One share of RNO stock can currently be purchased for approximately $0.36.

3. How can I contact Rhinomed?

Rhinomed's mailing address is 132 Gwynne Street Level 1 Cremorne Richmond VIC 3121 Australia. The company can be reached via phone at 61 3 8416 0900.

4. What is Rhinomed's official website?

The official website of Rhinomed is http://www.rhinomed.global.

5. Which share registry manages Rhinomed's stock?

Rhinomed's stock is managed by AUTOMIC REGISTRY SERVICES.